The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: A historical cohort analysis of a generic COX-2 selective inhibitor

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 13, Issue 4, 2008, Pages 252-260

  Warner, John J ^a   Weideman, Rick A ^b   Kelly, Kevin C ^b   Brilakis, Emmanouil S ^a,b   Banerjee, Subhash ^a,b   Cunningham, Francesca ^c   Harford, William V ^a,b   Kazi, Salahuddin ^a,b   Little, Bertis B ^b,d   Cryer, Byron ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d TARLETON STATE UNIVERSITY   (United States)

Author keywords

AMI; Celecoxib; Cohort; COX 2; Epidemiology; Etodolac; Naproxen; Rofecoxib

Indexed keywords

CELECOXIB; ETODOLAC; NAPROXEN; ROFECOXIB;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DRUG UTILIZATION REVIEW; DRUGS, GENERIC; ETODOLAC; HUMANS; INCIDENCE; LACTONES; MALE; MEDICAL RECORDS; MIDDLE AGED; MYOCARDIAL INFARCTION; NAPROXEN; PREVALENCE; PROGNOSIS; PYRAZOLES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SULFONAMIDES; SULFONES; TEXAS; VETERANS;

EID: 57649217921     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248408323136     Document Type: Article

References (24)

1. Antman EM, Bennett JS, Daugherty A., Furberg C., Roberts H., Taubert KA Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007 ; 115: 1634-1642.
2. American College of Rheumatology. ACR HOTLINE: The Safety of COX-2 Inhibitors: Delibertions from the February 16-18, 2005, FDA Meeting. http://www.rheumatology.org/publications/hotline/0305COX2.pdf. Accessed August 20, 2008.
3. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000 ; 343: 1520-1528.
4. Solomon DH, Glynn RJ, Levin R., Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002 ; 162: 1099-1104.
5. Kimmel SE, Berlin JA, Reilly M., et al. The effects of non-selective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol. 2004 ; 43: 985-90.
6. Rahme E., Pilote L., LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 2002 ; 162: 1111-1115.
7. Juni P., Nartey L., Reichenbach S., Sterchi R., Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004 ; 364: 2021-2029.
8. Mamdani M., Rochon P., Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003 ; 163: 481-486.
9. Ray WA, Stein CM, Hall K., Daugherty JR, Griffin MR Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet. 2002 ; 359: 118-123.
10. Graham DJ, Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective anti-inflammatory drugs: nested case-control study. Lancet. 2005 ; 365: 475-481.
11. Kearney PM, Baigent C., Godwin J., Halls H., Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006 ; 332: 1302-1308.
12. McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase. JAMA. 2006 ; 296: 1633-1644.
13. Farkouh ME, Kirshner H., Harrington RA Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet. 2004 ; 364: 675-684.
14. Bresalier RS, Sandler RS, Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005 ; 352: 1092-1102.
15. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 ; 352: 1071-1080.
16. Warner TD, Giuliano F., Vojnovic I., Bukasa A., Mitchell JA, Vane JR Nonsteriod drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999 ; 96: 7563-7568.
17. Neustadt DH Double blind evaluation of the longterm effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. J Rheumatol. 1997 ;(suppl 47) 24: 17-22.
18. Weideman RA, Kelly KC, Kazi S., et al. Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. Gastroenterology. 2004 ; 127: 1322-1328.
19. Laine L., Sloane R., Ferretti M., Cominelli F. A randomized, double-blind comparison of placebo, etodolac, and naproxen on grastrointestinal injury and prostaglandin production. Gastrointest Endosc. 1995 ; 42: 428-433.
20. Motsko SP, Rascati KL, Busti AJ, et al. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf. 2006 ; 29: 621-632.
21. Ray WA, Stein CM, Daugherty JR, Hall K., Arbogast PG, Griffin MR COX-2 selective non-steroidalantiinflammatory drugs and risk of serious coronary heart disease. Lancet. 2002 ; 360: 1071-1073.
22. Solomon SD, Wittes J., Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008 ; 117: 2104-2113.
23. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001 ; 345: 433-442.
24. Haffner SM, Lehto SE, Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 ; 339: 229-234.